Resumo

RODRIGUEZ ROSALES, Solem et al. Effectiveness of Heberferon in the treatment of basal cell carcinoma. Multimed [online]. 2023, vol.27  Epub 11-Maio-2023. ISSN 1028-4818.

Basal cell carcinoma is the most frequent skin cancer in humans, representing approximately between 70 and 80% of non-melanoma skin cancers in the white-skinned population, this is a malignant tumor of epithelial lineage and is the most frequent in dermatological consultation, usually affecting individuals over 50 years of age with maximum incidence between the sixth and eighth decade of life. A post-marketing study was conducted, observational, case series, of early surveillance of the drug under conditions of routine medical practice. The research was carried out with patients diagnosed with basal cell carcinoma, attended in the consultation in the oncodermatology consultation, which has its headquarters Hospital ‟Carlos Manuel de Céspedes" of Bayamo, during the period from January 2018 to December 2019. The universe consisted of 120 patients and the sample was 92 patients over 18 years of age, who were administered HeberFERON, proving to be effective in the treatment of basal cell carcinoma of any location, type and size. The effectiveness in conditions of usual medical practice was confirmed, in the variables: clinical response to treatment, using the RECIST criteria, in addition to showing an adequate safety profile. The adverse events reported were mostly grade 1 and grade 2, according to the classification of the CTCAE, version 5 and due to their severity, they were classified as non-serious.

Palavras-chave : Heberferon; Effectiveness; Basal cell carcinoma.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )